Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer

Inclusion Criteria: * Histological or cytological diagnosis of non-small cell carcinoma of the lung * Initially unresectable non-metastatic stage III disease * Availability for participating in the detailed follow-up of the protocol * Presence of an evaluable or measurable lesion * Written informed consent * No functional or anatomical contraindication to chest irradiation Exclusion Criteria: * Prior treatment with chemotherapy, radiotherapy or surgery * Performance status \< 60 on the Karnofsky scale * History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval) * Neutrophils \< 2,000/mm³ * Platelet cells \< 100,000/mm3 * Serum bilirubin \> 1.5 mg/100 ml * Hepatic disease contra-indicating the administration of docetaxel and/or GOT or GPT ≥ 2.5x the normal value and/or alkaline phosphatase ≥ 5x the normal value * Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 60 ml/min * Recent myocardial infarction (less than 3 months prior to date of diagnosis) or uncontrolled angina pectoris * Congestive cardiac failure or cardiac arrhythmia requiring medical treatment * Uncontrolled infectious disease * Symptomatic polyneuropathy * Auditive impairment contra-indicating cisplatin administration * Serious medical or psychological factors which may prevent adherence to the treatment schedule * Malignant pleural or pericardial effusion * Homolateral supraclavicular lymph node excepting upper lobe lesion * Heterolateral supraclavicular lymph node * Known hypersensitivity to docetaxel or cisplatin * Pregnancy or for pre-menopausal patient, incapacity to use adequate contraceptive method